SCHEMBL6287871

SCHEMBL6287871

CCCCCc1ccc(CCCO)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
ESR1 P03372 2/20 0.65
ADRA2A P08913 2/20 0.65
ADORA3 P0DMS8 2/20 0.65
TACR2 P21452 2/20 0.65
SLC6A2 P23975 2/20 0.65
SLC6A4 P31645 2/20 0.65
SLC6A3 Q01959 2/20 0.65
LMNA P02545 2/20 0.65
CYP3A4 P08684 2/20 0.65
KDM4E B2RXH2 1/20 0.65
SHBG P04278 1/20 0.65
TP53 P04637 1/20 0.65
HSPD1 P10809 1/20 0.65
ADRB3 P13945 1/20 0.65
HTR2C P28335 1/20 0.65
HSPE1 P61604 1/20 0.65
HIF1A Q16665 1/20 0.65
TST Q16762 1/20 0.65
HSD17B10 Q99714 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2726293 0.98 ESR1 (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL6282873 0.98 ESR1 (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL6285688 0.98 ESR1 (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL26239861 0.95 ALDH1A1 (0.65) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL9512491 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL6270009 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL18533218 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL8496112 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL15922494 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2
SCHEMBL10929763 0.93 LMNA (0.69) ALDH1A1ESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263742-A1 A LIPID Stemirna Therapeutics Co., Ltd. (CN) 2023-08-24 US disclosed
US-20230263742-A1 A LIPID Stemirna Therapeutics Co., Ltd. (CN) 2023-08-24 US disclosed
US-6911468-B2 Tyrosine phosphatase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-06-28 US disclosed
US-20030144338-A1 Tyrosine phosphatase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-07-31 US disclosed
EP-1284260-A1 TYROSINE PHOSPHATASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144338-A1 Tyrosine phosphatase inhibitors PTPRC, PTPN1, PTPRM ALDH1A1 2470/4885ESR1 3084/4885ADRA2A 4316/4885
US-20230263742-A1 A LIPID CETP, PLIN1, AUP1 ALDH1A1 1643/4885ESR1 4202/4885ADRA2A 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.